Poolbeg Pharma (POLB) Competitors

Poolbeg Pharma (LON:POLB) and Tissue Regenix Group (LON:TRX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, community ranking, earnings, media sentiment, dividends, risk and analyst recommendations.

Does the media prefer POLB or TRX?

In the previous week, Poolbeg Pharma's average media sentiment score of 0.00 equaled Tissue Regenix Group'saverage media sentiment score.

Company	Overall Sentiment
Poolbeg Pharma	Neutral
Tissue Regenix Group	Neutral

Which has preferable valuation & earnings, POLB or TRX?

Tissue Regenix Group has higher revenue and earnings than Poolbeg Pharma. Tissue Regenix Group is trading at a lower price-to-earnings ratio than Poolbeg Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Poolbeg Pharma	N/A	N/A	-£4.50B	-£851.82	0.00
Tissue Regenix Group	£31.98M	0.99	-£1.11M	-£0.97	-36.13

Does the MarketBeat Community prefer POLB or TRX?

Tissue Regenix Group received 162 more outperform votes than Poolbeg Pharma when rated by MarketBeat users. Likewise, 69.53% of users gave Tissue Regenix Group an outperform vote while only 0.00% of users gave Poolbeg Pharma an outperform vote.

Company	Underperform	Outperform
Poolbeg Pharma	Outperform Votes No Votes	Underperform Votes 1 100.00%
Tissue Regenix Group	Outperform Votes 162 69.53%	Underperform Votes 71 30.47%

Is POLB or TRX more profitable?

Poolbeg Pharma has a net margin of 0.00% compared to Tissue Regenix Group's net margin of -3.46%. Tissue Regenix Group's return on equity of -2.87% beat Poolbeg Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Poolbeg Pharma	N/A	-32.56%	-21.33%
Tissue Regenix Group	-3.46%	-2.87%	0.50%

Which has more volatility and risk, POLB or TRX?

Poolbeg Pharma has a beta of 2.11, meaning that its stock price is 111% more volatile than the S&P 500. Comparatively, Tissue Regenix Group has a beta of 1.61, meaning that its stock price is 61% more volatile than the S&P 500.

Do insiders & institutionals hold more shares of POLB or TRX?

1.2% of Poolbeg Pharma shares are held by institutional investors. Comparatively, 37.0% of Tissue Regenix Group shares are held by institutional investors. 24.7% of Poolbeg Pharma shares are held by company insiders. Comparatively, 47.3% of Tissue Regenix Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Tissue Regenix Group beats Poolbeg Pharma on 9 of the 12 factors compared between the two stocks.